Literature DB >> 24599993

Differential induction of apoptosis, interferon signaling, and phagocytosis in macrophages infected with a panel of attenuated and nonattenuated poxviruses.

Sandra Royo1, Bruno Sainz, Enrique Hernández-Jiménez, Hugh Reyburn, Eduardo López-Collazo, Susana Guerra.   

Abstract

UNLABELLED: Due to the essential role macrophages play in antiviral immunity, it is important to understand the intracellular and molecular processes that occur in macrophages following infection with various strains of vaccinia virus, particularly those used as vaccine vectors. Similarities as well as differences were found in macrophages infected with different poxvirus strains, particularly at the level of virus-induced apoptosis and the expression of immunomodulatory genes, as determined by microarray analyses. Interestingly, the attenuated modified vaccinia Ankara virus (MVA) was particularly efficient in triggering apoptosis and beta interferon (IFN-β) secretion and in inducing changes in the expression of genes associated with increased activation of innate immunity, setting it apart from the other five vaccinia virus strains tested. Taken together, these results increase our understanding of how these viruses interact with human macrophages, at the cellular and molecular levels, and suggest mechanisms that may underlie their utility as recombinant vaccine vectors. IMPORTANCE: Our studies clearly demonstrate that there are substantial biological differences in the patterns of cellular gene expression between macrophages infected with different poxvirus strains and that these changes are due specifically to infection with the distinct viruses. For example, a clear induction in IFN-β mRNA was observed after infection with MVA but not with other poxviruses. Importantly, antiviral bioassays confirmed that MVA-infected macrophages secreted a high level of biologically active type I IFN. Similarly, the phagocytic capacity of macrophages was also specifically increased after infection with MVA. Although the main scope of this study was not to test the vaccine potential of MVA as there are several groups in the field working extensively on this aspect, the characteristics/phenotypes we observed at the in vitro level clearly highlight the inherent advantages that MVA possesses in comparison to other poxvirus strains.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24599993      PMCID: PMC4019115          DOI: 10.1128/JVI.00468-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Cutting edge: long-term B cell memory in humans after smallpox vaccination.

Authors:  Shane Crotty; Phil Felgner; Huw Davies; John Glidewell; Luis Villarreal; Rafi Ahmed
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

2.  Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kappaB-responsive genes in infected HeLa cells.

Authors:  Susana Guerra; Luis A López-Fernández; Alberto Pascual-Montano; José Luis Nájera; Angel Zaballos; Mariano Esteban
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

Authors:  C F Ockenhouse; P F Sun; D E Lanar; B T Wellde; B T Hall; K Kester; J A Stoute; A Magill; U Krzych; L Farley; R A Wirtz; J C Sadoff; D C Kaslow; S Kumar; L W Church; J M Crutcher; B Wizel; S Hoffman; A Lalvani; A V Hill; J A Tine; K P Guito; C de Taisne; R Anders; W R Ballou
Journal:  J Infect Dis       Date:  1998-06       Impact factor: 5.226

4.  Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.

Authors:  J Schneider; S C Gilbert; T J Blanchard; T Hanke; K J Robson; C M Hannan; M Becker; R Sinden; G L Smith; A V Hill
Journal:  Nat Med       Date:  1998-04       Impact factor: 53.440

5.  Vaccinia virus infection attenuates innate immune responses and antigen presentation by epidermal dendritic cells.

Authors:  Liang Deng; Peihong Dai; Wanhong Ding; Richard D Granstein; Stewart Shuman
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

6.  Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.

Authors:  Igor M Belyakov; Patricia Earl; Amiran Dzutsev; Vladimir A Kuznetsov; Michael Lemon; Linda S Wyatt; James T Snyder; Jeffrey D Ahlers; Genoveffa Franchini; Bernard Moss; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-17       Impact factor: 11.205

7.  Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells.

Authors:  Susana Guerra; Luis A López-Fernández; Raquel Conde; Alberto Pascual-Montano; Keith Harshman; Mariano Esteban
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

8.  Cellular gene expression survey of vaccinia virus infection of human HeLa cells.

Authors:  Susana Guerra; Luis A López-Fernández; Alberto Pascual-Montano; Manuel Muñoz; Keith Harshman; Mariano Esteban
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

Review 9.  Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors.

Authors:  Genoveffa Franchini; Sanjay Gurunathan; Lynn Baglyos; Stanley Plotkin; Jim Tartaglia
Journal:  Expert Rev Vaccines       Date:  2004-08       Impact factor: 5.217

10.  Interaction of influenza virus with mouse macrophages.

Authors:  B Rodgers; C A Mims
Journal:  Infect Immun       Date:  1981-02       Impact factor: 3.441

View more
  7 in total

1.  Interference with SAMHD1 Restores Late Gene Expression of Modified Vaccinia Virus Ankara in Human Dendritic Cells and Abrogates Type I Interferon Expression.

Authors:  Katja Sliva; Judith Martin; Christine von Rhein; Tobias Herrmann; Anastasia Weyrich; Masako Toda; Barbara S Schnierle
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

2.  Differential Innate Immune Signaling in Macrophages by Wild-Type Vaccinia Mature Virus and a Mutant Virus with a Deletion of the A26 Protein.

Authors:  Siti Khadijah Kasani; Huei-Yin Cheng; Kun-Hai Yeh; Shu-Jung Chang; Paul Wei-Che Hsu; Shu-Yun Tung; Chung-Tiang Liang; Wen Chang
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

3.  Vaccinia Virus Encodes a Novel Inhibitor of Apoptosis That Associates with the Apoptosome.

Authors:  Melissa R Ryerson; Monique M Richards; Marc Kvansakul; Christine J Hawkins; Joanna L Shisler
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

4.  Suppression of NYVAC Infection in HeLa Cells Requires RNase L but Is Independent of Protein Kinase R Activity.

Authors:  Mercedes Fernández-Escobar; José Luis Nájera; Sara Baldanta; Dolores Rodriguez; Michael Way; Mariano Esteban; Susana Guerra
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

5.  Modified Vaccinia virus Ankara but not vaccinia virus induces chemokine expression in cells of the monocyte/macrophage lineage.

Authors:  Michael H Lehmann; Philip J R Price; Christine Brandmüller; Gerd Sutter
Journal:  Virol J       Date:  2015-02-12       Impact factor: 4.099

6.  Anti-apoptotic Bcl-XL but not Mcl-1 contributes to protection against virus-induced apoptosis.

Authors:  Michaela Ohmer; Arnim Weber; Gerd Sutter; Katrin Ehrhardt; Albert Zimmermann; Georg Häcker
Journal:  Cell Death Dis       Date:  2016-08-18       Impact factor: 8.469

7.  Modulation of Cell Surface Receptor Expression by Modified Vaccinia Virus Ankara in Leukocytes of Healthy and HIV-Infected Individuals.

Authors:  Adrien Leite Pereira; Quentin Jouhault; Ernesto Marcos Lopez; Antonio Cosma; Olivier Lambotte; Roger Le Grand; Michael H Lehmann; Nicolas Tchitchek
Journal:  Front Immunol       Date:  2020-09-08       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.